Beijing Tong Ren Tang Chinese Medicine Co Ltd (HK:3613)
:3613
Want to see HK:3613 full AI Analyst Report?
3613 Stock Chart & Stats
HK$8.61
-HK$0.07(-0.87%)
At close: 4:00 PM EST
HK$8.61
-HK$0.07(-0.87%)
Day’s Range― - ―
52-Week RangeHK$7.06 - HK$9.72
Previous CloseN/A
Volume609.00K
Average Volume (3M)1.10M
Market Cap
HK$5.98B
Enterprise ValueHK$3.88B
Total Cash (Recent Filing)HK$2.28B
Total Debt (Recent Filing)HK$126.54M
Price to Earnings (P/E)21.8
Beta0.69
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.04%
Share Statistics
EPS (TTM)0.38
Shares Outstanding837,100,000
10 Day Avg. Volume975,850
30 Day Avg. Volume1,095,238
Financial Highlights & Ratios
PEG Ratio-0.82
Price to Book (P/B)1.69
Price to Sales (P/S)4.68
P/FCF Ratio8.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.50Price Target Upside21.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.65
Revenue Forecast (FY)HK$1.81B
Bulls Say, Bears Say
Bulls Say
Very Low LeverageAn exceptionally low debt-to-equity (~0.03) gives durable financial flexibility. Over the next 2–6 months this supports capital allocation optionality—funding store investment, product rollouts, dividends or opportunistic M&A—while limiting refinancing and interest-rate stress.
Sustained Profit MarginsConsistently high gross and operating margins indicate structural pricing power and efficient manufacturing/retail mix. Margins provide a durable buffer versus revenue swings, enabling funding of marketing, R&D, and steady shareholder distributions through cyclical softness.
Improved Cash Generation In 2025A sharp improvement in 2025 operating and free cash flow strengthens the company's ability to self-fund working capital, capex and dividends. Sustained FCF increases resilience and lowers reliance on external capital over the medium term.
Bears Say
Revenue DeclineAn 11.4% revenue drop in 2025 signals weakening demand or pricing/mix pressure. If top-line weakness persists, it can erode operating leverage and force margin tradeoffs, reducing capacity to invest in stores, product development or marketing over coming quarters.
Falling ROEROE sliding to ~9.5% from prior highs suggests declining returns on the company’s capital base. Lower ROE may reflect weaker pricing, competitive pressures or capital inefficiency, limiting long-term shareholder value creation unless operational fixes raise returns.
Cash-flow VolatilityEpisodes of negative OCF/FCF despite reported earnings show cash-conversion risk from working-capital swings. Volatile cash flow reduces predictability for reinvestment and dividends and could force short-term liquidity measures during stress periods.
Beijing Tong Ren Tang Chinese Medicine Co News
3613 FAQ
What was Beijing Tong Ren Tang Chinese Medicine Co Ltd’s price range in the past 12 months?
Beijing Tong Ren Tang Chinese Medicine Co Ltd lowest stock price was HK$7.06 and its highest was HK$9.72 in the past 12 months.
What is Beijing Tong Ren Tang Chinese Medicine Co Ltd’s market cap?
Beijing Tong Ren Tang Chinese Medicine Co Ltd’s market cap is HK$5.98B.
When is Beijing Tong Ren Tang Chinese Medicine Co Ltd’s upcoming earnings report date?
Beijing Tong Ren Tang Chinese Medicine Co Ltd’s upcoming earnings report date is Aug 07, 2026 which is in 75 days.
How were Beijing Tong Ren Tang Chinese Medicine Co Ltd’s earnings last quarter?
Beijing Tong Ren Tang Chinese Medicine Co Ltd released its earnings results on Mar 20, 2026. The company reported HK$0.194 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.194.
Is Beijing Tong Ren Tang Chinese Medicine Co Ltd overvalued?
According to Wall Street analysts Beijing Tong Ren Tang Chinese Medicine Co Ltd’s price is currently Undervalued.
Does Beijing Tong Ren Tang Chinese Medicine Co Ltd pay dividends?
Beijing Tong Ren Tang Chinese Medicine Co Ltd pays a Annually dividend of HK$0.35 which represents an annual dividend yield of 4.04%. See more information on Beijing Tong Ren Tang Chinese Medicine Co Ltd dividends here
What is Beijing Tong Ren Tang Chinese Medicine Co Ltd’s EPS estimate?
Beijing Tong Ren Tang Chinese Medicine Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beijing Tong Ren Tang Chinese Medicine Co Ltd have?
Beijing Tong Ren Tang Chinese Medicine Co Ltd has 837,100,000 shares outstanding.
What happened to Beijing Tong Ren Tang Chinese Medicine Co Ltd’s price movement after its last earnings report?
Beijing Tong Ren Tang Chinese Medicine Co Ltd reported an EPS of HK$0.194 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.891%.
Which hedge fund is a major shareholder of Beijing Tong Ren Tang Chinese Medicine Co Ltd?
Currently, no hedge funds are holding shares in HK:3613
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beijing Tong Ren Tang Chinese Medicine Co Ltd
Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of Chinese medicine and healthcare products to wholesalers and individuals. The company operates through three segments: Hong Kong, Mainland China, and Overseas. It also offers Chinese medical consultation and treatment services. The company operates 23 retail outlets in Hong Kong and 46 retail outlets in other countries and regions in Asia, Oceania, North America, and Europe. It markets its products under the Tong Ren Tang brand. The company was founded in 1669 and is based in Wan Chai, Hong Kong.
3613 Stock 12 Month Forecast
Average Price Target
HK$10.50
▲(21.95% Upside)
Technical Analysis
China Traditional Chinese Medicine Holdings Co
―
Tong Ren Tang Technologies Co
―
Modern Chinese Medicine Group Co. Ltd.
―
Gushengtang Holdings Limited
―
Shandong Xinhua Pharmaceutical Company Limited Class H
―
Options Prices
Currently, No data available
---